ARCH Venture Partners β Full Portfolio
230 tracked investments Β· page 2 of 2 Β· listed companies and verified rows first
SciNeuro develops targeted therapeutics for neurodegenerative and age-related brain diseases by integrating patient genetics, health history, and advanced diagnostic tools.
BiotechDeep TechDigital HealthLongevityMedical DevicesRockville, US
Min Li(CEO & Director)inSam Agus(CSO/CMO)Paul Stead(CBO)in
Co-investorsLAV
Cambridge, MA biotech developing stem cell-derived islet therapy plus an immune-protective device for type 1 diabetes; acquired by Vertex for $950M.
BiotechCambridge, US
Robert Millman(Executive Officer, Director)
BoardTodd Foley(Executive Officer, Director)inMitch Finer(Director)Stephen Knight(Director)inJim Scopa(Director)William Sahlman(Director)
Co-investorsF-Prime CapitalJDRF T1D FundORI CapitalSlater Technology FundEight Roads VenturesMPM BioImpact
Singleron Biotechnologies develops single-cell and single-nucleus sequencing kits and solutions for transcriptome analysis of biological samples.
BiotechMedical DevicesCologne, DE
Co-investorsLAVLilly Asia VenturesLake Bleu CapitalMSA CapitalSBCVCSherpa Healthcare Partners
Singular Genomics develops spatial pathology technology to map molecules and cells directly in tissue for disease characterization.
BiotechDeep TechMedical Devices
John Stark(CEO)Aaron Berlin(CTO)in
Co-investorsCatalio Capital Management, LPCoatue ManagementF-Prime Capital
Sironax is a biopharmaceutical company focused on the discovery and development of therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases.
BiotechHealthtechLongevityWaltham, US
Dr. Xiaodong Wang(Founder)Dr. Zhiyuan Zhang(Founder)
Co-investorsF-Prime CapitalYuanBio Venture CapitalCBC GroupEight Roads VenturesFuture InnovationGaorong Capital+5 more
Sonoma provides a governance platform for enterprise deployments of AI agents built on the Model Context Protocol (MCP), offering a self-service MCP catalog, workflow builder, entitlement policies, audit logging, and security controls such as supply chain scanning and prompt injection protection.
AI & Machine LearningCybersecurityEnterprise Software
Stephen Cobbe(Founder)in
Co-investorsGoAhead VenturesHawk Hill Ventures8VCAlexandriaLifeforce Capital
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Jeffrey Bluestone(Executive Officer, Director, Promoter)in
BoardFan Yu(Director)Maggie Wilderotter(Director)Toni Hoover(Director)Terry Rosen(Director)Richard Klausner(Director)
Co-investors8VCFrazier Life SciencesJDRF T1D FundLAVLifeforce CapitalLilly Asia Ventures+1 more
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound enhancing agents) to deliver genetic payloads to targeted sites in a redosable manner.
BiotechDeep TechDigital Health
Kenneth Greenberg(Founder)in
Co-investorsLeaps by BayerSymBiosisUCB VenturesVida VenturesVivo Capital
Biotechnology company developing blood-based diagnostic tests for neurological disorders and early-stage cancer.
Cambridge, US
Co-investorsClavystBioPolaris Partners
Synchron develops brain-computer interface technology delivered via catheter to restore or improve motor and cognitive function in people with impairment or decline.
BiotechDeep TechMedical DevicesCampbell, US
Thomas James Oxley(Executive Officer, Director)Nicholas Opie(Director)inThomas Oxley(Founder)in
BoardRahul Sharma(Director)Alex Morgan(Director)inMartin Dieck(Director)
Co-investorsForepont Capital PartnersID8 InvestmentsKaleida CapitalKhosla VenturesBezos ExpeditionsIn-Q-Tel+4 more
Syndex develops mcPCR (methyl copying PCR), a proprietary platform technology that amplifies DNA while preserving methylation patterns, addressing the challenge of low DNA levels in clinical samples.
BiotechDeep TechMedical DevicesSanta Monica, US
Geoff Smith(Founder & CEO)inJason Betley(Chief Product Officer)in
Co-investorsOMX Ventures+ND Capital
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
Co-investorsAisling CapitalQuan CapitalFlagship VenturesREDMILE
Thermo Fisher provides life science products and laboratory equipment, including antibodies, consumables, biobanking resources, and Cryo-EM imaging systems for research labs and scientists.
BiotechEnterprise SoftwareHardwareHealthtechWaltham, US
Anthony Uzzo(Executive Officer, Director)inJoshua Geballe(Executive Officer, Director)James Gregory(Executive Officer, Director)Marc N. Casper(Executive Officer, Director)inAndrew J. Thomson(Executive Officer)Peter M. Wilver(Executive Officer)
Co-investorsBayMed Venture PartnersCross Creek AdvisorsExcel Venture ManagementHeran PartnersOak HC/FTDomain Associates+2 more
Hong Kong-listed, Suzhou-headquartered biopharmaceutical company developing antibody therapeutics with in-house biomanufacturing.
Xueming Qian(Founder)in
Co-investorsChina Structural Reform FundFortune Venture Capital
Transcripta Bio develops medicines for patients with serious diseases by mapping how molecules affect human cells at single-cell resolution.
AI & Machine LearningBiotechDeep Tech
Co-investorsBlueYard CapitalJAZZ Venture PartnersDCVC BioInsight Partners
Trase builds AI systems with built-in governance and auditability for organizations in high-stakes domains such as defense, healthcare, and critical infrastructure.
AI & Machine LearningDeep TechDefense TechEnterprise Software
Joe Laws(Co-Founder and Chief Architect)inGrant Verstandig(Co-Founder and CEO)in
Trase Systems builds AI software that is secure by design and governed from the start, integrating with an organization's data and infrastructure.
AI & Machine LearningDefense TechEnterprise SoftwareHealthtech
Co-investorsRed Cell Incubation
Treeline Biosciences is a drug discovery and development company focused on designing therapeutics for cancer patients.
AI & Machine LearningBiotechHealthtech
Jeff(Co-founder)Josh Bilenker(Founder)in
Co-investorsGV (Google Ventures)OrbiMed
San Diego biotech founded in 2019 developing oral anti-inflammatory small molecules targeting RNA binding proteins.
Co-investorsLightstone VenturesMedical Excellence Capital
VBI Vaccines is a biopharmaceutical company developing vaccine candidates using virus-like particle (VLP) platforms, including proprietary enveloped VLP and mRNA-launched eVLP technologies.
BiotechHealthtechCambridge, US
Marc Kirchmeier(Vice President, Formulation Development)Egidio Nascimento(Chief Financial Officer)inDavid Anderson(Senior Vice President, Research)inJeff Baxter(President and Chief Executive Officer)inAdam T. Buckley(Vice President, Business Development)inMurray G. Smith(Executive Officer)
Co-investors5AM VenturesClarus VenturesK2 HealthVentures
Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.
BiotechCambridge, US
Andrew Ashe(Executive Officer)Sekar Kathiresan(Executive Officer, Director)inAndrew Bellinger(Executive Officer)
BoardJohn Evans(Director)Anthony Philippakis(Director)inKrishna Yeshwant(Director)in
Co-investorsF-Prime CapitalGV (Google Ventures)RA CapitalvenBio PartnersCasdin CapitalForesite Capital
Vesalius Therapeutics develops a computational platform that identifies distinct disease subtypes within common diseases like heart failure, diabetes, and Alzheimer's by analyzing patient data and gene circuits, then uses proprietary cell-based models to discover targeted drug candidates.
AI & Machine LearningBiotechDeep TechCambridge, US
Yasir Al-Wakeel(CEO)in
Co-investorsFlagship PioneeringSofinnova Ventures
Vilya designs novel macrocycles using AI and computational biology to create medicines that don't exist in nature.
AI & Machine LearningBiotechDeep Tech
David Baker(Scientific Founder)Patrick Salveson, PhD(Co-Founder, CTO)Adam Moyer, PhD(Co-Founder, VP of Molecular Design)David Baker, PhD(Nobel laureate, Co-Founder, Director, IPD UW, Prof. Biochemistry)Gaurav Bhardwaj, PhD(Co-Founder, UW, Asst. Prof. Medicinal Chemistry)Lance Stewart, PhD, MBA(Co-Founder, CSO & COO, IPD)
Co-investorsMadrona Venture GroupMenlo VenturesNVenturesNVIDIA
Volastra Therapeutics is a drug discovery and development company working on novel cancer therapies.
BiotechHealthtechNew York, US
Samuel Bakhoum(Co-Founder & Chief Scientific Officer)inLewis Cantley(Founder and Chair of Scientific Advisory Committee)Olivier Elemento(Founder and Scientific Advisor)David P. Southwell(Chief Executive Officer)in
BoardRobert Mittendorff(Director)inJill Goldstein(Director)in
Co-investorsDroia VenturesB Capital GroupB4 CapitalVida VenturesPolaris Partners
.jpeg){kind=logo}
Walden Biosciences is a clinical-stage biotech company developing disease-modifying therapies that selectively target the kidney to treat the underlying drivers of kidney disease.
BiotechMedical Devices
Co-investorsPandect Bioventures
Xaira develops AI and machine learning tools for drug discovery and protein design, serving pharmaceutical and biotech companies.
AI & Machine LearningBiotechMedical DevicesSouth San Francisco, US
Hetu Kamisetty(Founder)Marc Tessier-Lavigne(Chairman & Chief Executive Officer)inDr. Ci Chu(Chief Discovery Officer)Dr. Bo Wang(Chief AI Scientist)Dr. Ian McCaffery(SVP, Translational Science and Early Clinical Development)
Co-investorsBreyer CapitalF-Prime CapitalForesite CapitalLongwood FundMenlo VenturesNew Enterprise Associates (NEA)+1 more
Other
Tracked investments with no reachable website or further public details β typically companies that wound down, renamed, or were absorbed.
SciNeuroSorbent TherapeuticsTome BiosciencesUltraDx Bio
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.